Kymriah
Tisagenlecleucel
Disease: Large B-cell lymphoma
Indication: Patients up to 25 years of age with B-cell precursor acute lymphoblasticleukemia (ALL) that is refractory or in second or later relapse.
Company: Novartis Pharmaceuticals
- Market Cap: $198.098B Oct 2020
Methods: Patient’s T cells are modified to recognize CD19 on B cells, expanded, and reintroduced to the patient to combat Large B-cell Lymphoma.
Link to the clinical trial: NCT04161118
Link to company R&D pipeline: https://www.novartis.com/our-science/novartis-global-pipeline
Package Insert: https://www.fda.gov/media/107296/download
Current Phase: FDA Approved
Subscribe to Our Newsletter
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
[formidable id=9]
